

**TABLE S1, SDC**

PICO #	Patient Population	Intervention	Comparator	Outcome(s)
<b>WAIT LISTED PATIENTS</b>				
1	Wait-listed with compensated cirrhosis and HCC	Antiviral Therapy (i.e. pre vs post)	No antiviral therapy	HCC Progression pre and post-LT Wait-list mortality Survival post-LT SVR
2	Wait-listed with decompensated cirrhosis without HCC	Antiviral Therapy (i.e. pre vs post)	No antiviral therapy	Wait-list survival Post-LT survival HCV recurrence post-LT HCC progression prepost Improvement in decompensation SVR
3	Wait-listed with decompensated cirrhosis and HCC	Antiviral Therapy (i.e. pre vs post)	No antiviral therapy	HCC Progression pre and post-LT Wait-list mortality Survival post-LT Improvement in decompensation SVR
<b>LIVER TRANSPLANT RECIPIENTS</b>				
6	Vlremic post-LT	Antiviral therapy early (prior to disease)	Antiviral therapy upon documentation of significant disease	Posttransplant survival Cholestatic hepatitis SVR Advanced fibrosis Extrahepatic complications
5	Post-LT with cholestatic hepatitis	Antiviral therapy with SOF/NS5A ± RBV	Antiviral therapy with other drug classes	Post-transplant survival including re-LT SVR Advanced fibrosis
7	Post-LT recurrent cirrhosis	Antiviral therapy	No antiviral therapy	Survival Improvement in decompensation SVR
<b>SPECIAL POPULATIONS</b>				
4	HCV-HIV coinfectd patient	Antiviral therapy (i.e. pre vs post)	No antiviral therapy	Wait-list survival Post-LT survival SVR
5	HCV positive and negative recipient	HCV positive donor	HCV negative donor	Wait-list survival Post-LT survival HCV infection